GJB2 and deafness: For instance, gene replacement strategies for OTOF variations have reached the stage of clinical trials, and preclinical studies have demonstrated the potential of gene editing, antisense oligonucleotides, and RNA-based therapies for other genes associated with deafness, such as GJB2 and MYO7A.